ResMed Inc. ($RMD) Stock Forecast: Up 2.6% Today

What is ResMed Inc.?

ResMed Inc. (RMD) is a leading medical equipment provider specializing in sleep technology solutions. The company has recently reported strong quarterly results, exceeding expectations and announcing a quarterly dividend.

Why is ResMed Inc. going up?

RMD stock is up 2.6% on Feb 4, 2026 15:47

• Institutional investors acquiring significant stakes in ResMed Inc. indicate growing confidence in the company's future prospects, contributing to the bullish movement.
• Despite insider selling trends, the positive quarterly results and dividend announcement have likely boosted investor sentiment towards ResMed.
• Emphasizing ResMed as a stable long-term investment in the healthcare sector reinforces the positive market movement, attracting more investors to the stock.
• The overall bullish sentiment towards ResMed is further supported by the insider sell alert, which, despite the selling activity, did not deter investors, possibly due to the company's strong fundamentals and growth potential.

RMD Price Chart

RMD Technical Analysis

RMD News

Allianz Asset Management GmbH Acquires 110,647 Shares of ResMed Inc. $RMD

Allianz Asset Management GmbH significantly increased its stake in ResMed Inc. (NYSE:RMD) by 44.8% in the third quarter, acquiring an additional 110,647 shares to reach a total of 357,421 shares valued at approximately $97.8 million. This acquisition occurred amid continued insider selling from ResMed executives. The medical equipment provider recently reported strong quarterly results, exceeding EPS and revenue estimates, and announced a quarterly dividend of $0.60 per share.

https://www.marketbeat.com/instant-alerts/filing-allianz-asset-management-gmbh-acquires-110647-shares-of-resmed-inc-rmd-2026-02-04/

WCM Investment Management LLC Makes New Investment in ResMed Inc. $RMD

WCM Investment Management LLC has acquired a new stake in ResMed Inc. (NYSE:RMD) by purchasing 11,474 shares valued at approximately $3.11 million. This comes as other institutional investors, such as Vanguard Group Inc. and State Street Corp, also increased their holdings in the medical equipment provider. Insider activity shows some stock sales by directors, while analysts have issued various price targets and ratings, with the stock currently holding a "Moderate Buy" consensus.

https://www.marketbeat.com/instant-alerts/filing-wcm-investment-management-llc-makes-new-investment-in-resmed-inc-rmd-2026-02-04/

Abbott Laboratories Stock Now 18% Cheaper, Time To Buy

Abbott Laboratories (ABT) stock is presented as a compelling buy opportunity, currently 18% cheaper based on its Price-to-Sales ratio compared to a year ago. The company demonstrates strong fundamentals including high operating cash flow and operating margins, especially in its Medical Devices segment, with new product launches expected to reaccelerate other areas. Despite past market drawdowns, ABT is highlighted for its consistent profitability and cash generation capacity, making it attractive for long-term investors seeking discounted quality.

https://www.trefis.com/stock/abt/articles2/589567/abbott-laboratories-stock-now-18-cheaper-time-to-buy/2026-02-04

The Truth About ResMed Inc.: Why Everyone Is Suddenly Paying Attention

This article examines ResMed Inc. (RMD), a sleep-tech company, to determine if its stock is a worthwhile investment. It evaluates ResMed's market position, competitive landscape against rivals like Philips, and its business model, which combines hardware and software for recurring revenue. The article concludes that ResMed is not a get-rich-quick stock but offers stable, long-term exposure to the growing healthcare sector focusing on sleep and respiratory issues.

https://www.ad-hoc-news.de/boerse/news/ueberblick/the-truth-about-resmed-inc-why-everyone-is-suddenly-paying-attention/68549936

Insider Sell Alert: Brett Sandercock Sells Shares of ResMed Inc (RMD)

Brett Sandercock, CFO of a ResMed Inc subsidiary, sold 1,000 shares of ResMed Inc (RMD) on February 2, 2026, reducing his holding to 85,495 shares. This sale is part of a trend for Sandercock, who has sold 26,527 shares over the past year with no purchases, contributing to a total of 47 insider sells at ResMed Inc during the same period. The stock is currently trading at $257.03, which is considered fairly valued based on its GuruFocus Value.

https://www.gurufocus.com/news/8579051/insider-sell-alert-brett-sandercock-sells-shares-of-resmed-inc-rmd

Trending Today

StoneCo Ltd. ($STNE) Stock Forecast: Down 5.4% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 38.0% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Down 5.6% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Down 11.8% Today

DaVita Inc. ($DVA) Stock Forecast: Up 6.6% Today

Lemonda Inc. ($LMND) Stock Forecast: Down 10.2% Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Up 5.5% Today

Voya Financial Inc. ($VOYA) Stock Forecast: Down 7.6% Today

Wynn Resorts Limited ($WYNN) Stock Forecast: Up 5.1% Today

Deutsche Bank AG ($DB) Stock Forecast: Down 5.1% Today

ResMed Inc. Price History

30.00.2026 - RMD Stock was down 0.8%

• The strong bearish movement in ResMed's stock today could be attributed to profit-taking by investors after a period of positive performance and price appreciation.
• Despite the impressive Q2 results and increased institutional interest in the company's stock, the notable insider selling by CEO Michael J. Farrell and others might have raised concerns among investors about the future outlook of the company.
• Additionally, the market may be reacting to the Hold rating reiterated by an independent analyst, indicating a more cautious stance on the stock despite the positive financial performance.
• Overall, the bearish movement could be a result of a combination of factors, including profit-taking, insider selling, and cautious analyst sentiment, leading to a temporary dip in the stock price.

13.00.2026 - RMD Stock was down 0.3%

• Bogart Wealth LLC notably increased its stake in ResMed Inc., while company insiders have been selling shares possibly suggesting differing views on the company's potential.
• ResMed's robust Q3 earnings report and revenue growth might have initially boosted investor confidence, but recent insider selling by the CEO and a director could have raised concerns.
• The sale of shares by ResMed director Peter C. Farrell under a pre-arranged trading plan, amid varied analyst ratings, could have intensified the negative sentiment surrounding the stock.
• Despite the positive earnings and institutional investments, the mixture of analyst ratings, insider selling, and market apprehensions about the company's future likely contributed to the bearish movement in ResMed's stock price today.

05.00.2026 - RMD Stock was up 1.3%

• The significant insider selling and institutional ownership of ResMed Inc. could have initially raised concerns among investors, but the company's ability to surpass EPS and revenue expectations likely reassured the market.
• ResMed's strategic shift towards a connected ecosystem for sleep and respiratory care may have sparked investor optimism about the company's long-term growth potential and competitive edge.
• The high institutional ownership, particularly with influential shareholders like The Vanguard Group, Inc., suggests a level of confidence in ResMed's future performance, potentially contributing to the bullish movement in the stock.
• Overall, the combination of positive financial results, strategic positioning in the market, and strong institutional support likely drove the bullish momentum in ResMed's stock today.

05.02.2025 - RMD Stock was down 2.9%

• Today, ResMed's stock experienced a notable bearish trend, potentially due to investors engaging in profit-taking following a substantial 25.6% increase over the past year. Despite the success of the AirSense platform fueling positive momentum, market participants may have chosen to secure their profits, resulting in downward pressure on the stock price.

24.03.2025 - RMD Stock was up 5.1%

• ResMed reported stellar third-quarter fiscal 2025 results, surpassing earnings and revenue estimates, showcasing strong execution across all business areas.
• The appointment of Salli Schwartz as Chief Investor Relations Officer could have instilled confidence in investors, signaling a focus on transparent communication and investor relations.
• The positive market reaction indicates that investors are optimistic about ResMed's future prospects and growth trajectory, driven by robust financial performance and strategic leadership appointments.

31.09.2025 - RMD Stock was down 6.1%

• Despite ResMed (RMD) beating earnings and revenue estimates for Q1, the stock experienced a bearish movement.
• The options market activity suggests that there might be some uncertainty or negative sentiment surrounding the stock.
• Investors may be reacting to factors beyond the quarterly performance, such as future growth projections or market conditions.
• The bearish movement could also be influenced by profit-taking activities following a period of positive performance.

04.01.2026 - RMD Stock was up 2.6%

• Institutional investors acquiring significant stakes in ResMed Inc. indicate growing confidence in the company's future prospects, contributing to the bullish movement.
• Despite insider selling trends, the positive quarterly results and dividend announcement have likely boosted investor sentiment towards ResMed.
• Emphasizing ResMed as a stable long-term investment in the healthcare sector reinforces the positive market movement, attracting more investors to the stock.
• The overall bullish sentiment towards ResMed is further supported by the insider sell alert, which, despite the selling activity, did not deter investors, possibly due to the company's strong fundamentals and growth potential.

08.03.2025 - RMD Stock was down 5.1%

• ResMed recently introduced NightOwl, an FDA-approved home sleep apnea test in the US. Nevertheless, the stock faced a decline in the market.
• Speculation from sources suggests the stock may not see further growth despite positive earnings estimate revisions.
• Investor expectations for ResMed's performance could have driven a sell-off of the stock following news of the successful product launch.

04.07.2025 - RMD Stock was up 4.0%

• ResMed (RMD) exceeded expectations in Q2 earnings, outperforming projections for both earnings per share and sales.
• Analysts have raised their forecasts for the company following the strong earnings report, signaling confidence in its future performance.
• Surpassing estimates for Q4 earnings and revenue reinforces ResMed's market position and indicates potential for further growth.
• The uptick in ResMed's stock price reflects its robust financial results and positive outlook for the future.

31.00.2025 - RMD Stock was down 5.8%

• ResMed (RMD) reported strong Q2 earnings and revenue surpassing expectations, but the stock faced a bearish trend.
• The stock's decline post-achieving a 52-week high could be attributed to profit-taking, causing a temporary decrease in price.
• Some investors are uncertain about the sustainability of ResMed's growth, leading them to sell shares despite positive financial performance.
• The bearish movement might also stem from broader market shifts or sector rotations, with investors temporarily diverting attention from healthcare stocks.

10.02.2025 - RMD Stock was up 5.2%

• The bullish movement in RMD can be attributed to the strong sales performance of its mask and device products, showcasing the company's ability to meet market demand effectively.
• The success of ResMed's cloud-connected AirSense platform has also played a significant role in driving investor confidence and contributing to the stock's impressive rally.
• Despite concerns about increasing debt levels, the market seems to be focusing more on the company's product innovation and industry outperformance, leading to the bullish movement in the stock.

07.03.2025 - RMD Stock was up 5.7%

• Resmed's stock saw a rise following the successful launch of NightOwl, a home sleep apnea test, in the US.
• The FDA-cleared diagnostic tool is expected to boost the company's market presence and revenue prospects in the sleep apnea sector.
• Investor reactions indicate faith in Resmed's cutting-edge products and its capacity to meet the increasing need for in-home healthcare remedies.